FY2030 EPS Estimate for Moderna Lowered by Analyst

Moderna, Inc. (NASDAQ:MRNA) – Investment analysts at Brookline Capital Markets decreased their FY2030 earnings per share estimates for shares of Moderna in a report issued on Thursday, October 22nd. Brookline Capital Markets analyst L. Cann now forecasts that the company will post earnings per share of $18.19 for the year, down from their previous estimate of $19.11. Brookline Capital Markets has a “Buy” rating on the stock. The consensus estimate for Moderna’s current full-year earnings is ($6.11) per share.

Moderna (NASDAQ:MRNA) last posted its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm had revenue of $145.00 million during the quarter, compared to analyst estimates of $102.93 million. During the same quarter in the prior year, the business posted ($2.13) EPS. The business’s revenue was up 2.1% compared to the same quarter last year.

Several other research analysts have also recently weighed in on MRNA. Bank of America boosted their price target on shares of Moderna from $170.00 to $200.00 and gave the stock a “neutral” rating in a report on Friday, October 9th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $150.00 price objective (up from $60.00) on shares of Moderna in a research report on Wednesday, August 19th. Barclays increased their price objective on shares of Moderna from $48.00 to $125.00 and gave the company an “equal weight” rating in a research note on Monday, August 24th. Berenberg Bank lifted their target price on shares of Moderna from $45.00 to $100.00 and gave the stock a “hold” rating in a research report on Friday, September 11th. Finally, Evercore lifted their target price on shares of Moderna from $50.00 to $80.00 in a research report on Thursday, October 8th. Seven research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat.com, Moderna has an average rating of “Hold” and a consensus target price of $107.10.

Moderna Trading Down 0.6%

Shares of MRNA stock opened at $198.85 on Monday. The firm has a 50-day moving average of $173.86 and a 200-day moving average of $82.87. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. Moderna has a one year low of $22.28 and a one year high of $254.48.

Insider Activity

In other news, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the sale, the insider directly owned 74,129 shares in the company, valued at $10,374,353.55. The trade was a 4.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 39,145 shares of the business’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $220.72, for a total transaction of $8,640,084.40. Following the completion of the transaction, the president directly owned 1,636,565 shares in the company, valued at $361,222,626.80. This trade represents a 2.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 197,251 shares of company stock valued at $33,875,904 in the last ninety days. 10.80% of the stock is currently owned by insiders.

Institutional Trading of Moderna

A number of large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new stake in Moderna in the second quarter worth about $2,142,877,000. Theleme Partners LLP purchased a new position in Moderna in the second quarter valued at about $564,272,000. Wellington Management Group LLP grew its position in shares of Moderna by 4.4% during the 2nd quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock valued at $172,384,000 after acquiring an additional 103,977 shares during the period. First Trust Advisors LP grew its position in shares of Moderna by 59.3% during the 1st quarter. First Trust Advisors LP now owns 2,392,693 shares of the company’s stock valued at $121,549,000 after acquiring an additional 891,072 shares during the period. Finally, Merck & Co. Inc. bought a new position in shares of Moderna during the 2nd quarter valued at approximately $161,642,545. Hedge funds and other institutional investors own 75.33% of the company’s stock.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: The Phase 3 INTerpath-001 trial met its primary endpoint. Adding intismeran to Merck’s Keytruda reduced the risk of melanoma recurrence or death by 42% versus Keytruda alone; the combination also reduced distant metastasis or death by 38%. The vaccine’s delayed improvement after six months could support the case for a durable immune response. Merck and Moderna’s Cancer Vaccine Worked—Who Gets Paid?
• Positive Sentiment: The melanoma program could become a major revenue source for Moderna if approved. Analysts cited in the coverage estimate peak annual melanoma sales of approximately $5.4 billion, with Moderna and Merck sharing development costs and profits equally. Regulatory filing timing and manufacturing plans are now key catalysts. Moderna and Merck’s Promising Skin Cancer Vaccine
• Neutral Sentiment: Investors are looking ahead to Moderna’s next earnings report for updates on losses, declining COVID revenue, product launches and the broader pipeline. The company remains unprofitable, making progress toward commercializing newer products especially important. What to Expect From Moderna’s Next Earnings Report
• Negative Sentiment: The Phase 3 benefit was below the roughly 49% recurrence reduction from the earlier study and below what investors had priced in. The resulting selloff suggests the stock’s valuation—largely based on future cancer-vaccine revenue—left little room for disappointment. Commercial execution is also unproven because each vaccine is individually manufactured for a patient. Moderna’s Rally May Have Run Out of Steam

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.